Charles River Laboratories | CRL - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Agilent USD 990M 44M 2026-03
Align Technology USD 736.59M 53M 2026-03
Bio-Rad Laboratories USD 345.2M 1.8M 2025-12
Bruker USD 379.8M 69.4M 2026-03
Cardinal Health USD 2.5B 101M 2026-03
Charles River Laboratories USD 279.32M 7.36M 2026-03
Cigna USD 6.08B 50.37B 2026-03
Concord Medical Services Hldg CNY -37.42M 26.25M 2023-06
CVS Health USD 15.62B 2.06B 2026-03
Danaher USD 3.59B 375M 2026-03
Dentsply International USD 427M 16M 2026-03
Elevance Health USD 11.68B 889M 2025-12
Humana USD 4.82B 754M 2025-06
Illumina USD 721M 38M 2026-03
Incyte USD 1.17B 217.51M 2026-03
Intrexon USD -297K 167K 2024-06
IQVIA Holdings USD 1.07B 52M 2026-03
Laboratory Of America USD 1.01B 20.6M 2026-03
Lakefront Biotherapeutics EUR 1.68M 898.68M 2026-03
Lonza CHF 1.29B 248M 2025-06
McKesson USD 3.68B 143M 2025-12
Merck EUR 3.07B 104M 2026-03
Mettler Toledo International USD 675.44M 65.98M 2025-12
Novartis USD 10.07B 184M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Quest Diagnostics USD 906M 33M 2026-03
Revvity USD 387.66M 34M 2026-03
Thermo Fisher Scientific USD 4.49B 146M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12
UnitedHealth USD 18.49B 2.14B 2025-12
Veradigm USD 83.44M 3.95M 2022-09
Waters USD 542M 15.42M 2026-03
West Pharmaceutical Services USD 296.4M 7.5M 2026-03